biostudies-literatureUnknown13(4)Wang RLung cancer is one of the most common malignant tumors and is currently the leading cause of cancer-related deaths worldwide. Although the treatment strategy has been significantly improved, the prognosis of lung cancer patients is still quite poor. RIOK1 has been reported to be highly expressed in non-small cell lung cancer (NSCLC), however, its clinical significance and biological function are still largely unknown in lung cancer. Using western blot and immunohistochemistry, we showed that RIOK1 was highly expressed in NSCLC tissues and correlated with advanced stage and poor prognosis. Furthermore, knockdown of RIOK1 could inhibit proliferation, migration, and invasion in NSCLC cells and tumorigenesis <i>in vivo</i> through AKT, Cyclin B1, MMP2, and EMT pathway. Furthermore, cell viabilJournal of Cancer1289-1298https://www.ebi.ac.uk/biostudies/studies/S-EPMC8899362biostudies-literatureRIOK1 is associated with non-small cell lung cancer clinical characters and contributes to cancer progression.PMC8899362Pan DZWang RPan SShan LNHe YHShi XChai WSfalseRIOK1 is associated with non-small cell lung cancer clinical characters and contributes to cancer progression.Lung cancer is one of the most common malignant tumors and is currently the leading cause of cancer-related deaths worldwide. Although the treatment strategy has been significantly improved, the prognosis of lung cancer patients is still quite poor. RIOK1 has been reported to be highly expressed in non-small cell lung cancer (NSCLC), however, its clinical significance and biological function are still largely unknown in lung cancer. Using western blot and immunohistochemistry, we showed that RIOK1 was highly expressed in NSCLC tissues and correlated with advanced stage and poor prognosis. Furthermore, knockdown of RIOK1 could inhibit proliferation, migration, and invasion in NSCLC cells and tumorigenesis <i>in vivo</i> through AKT, Cyclin B1, MMP2, and EMT pathway. Furthermore, cell viabil2022-01-01T00:00:00Z20222025-04-25T22:29:33.421Z2025-04-06T09:03:35.464ZS-EPMC88993623528187210.7150/jca.64668